How does Ferinject[®]

make a difference?

Effective restoration of iron levels^{1,9–32}

Proven data for efficacy and tolerability ^{1,9–32}

- Extensively studied in 26 interventional studies, published in peer-reviewed journals
- Market exposure estimated to > 2,200,000 patient years*

Rapid repletion of iron stores⁹

- More efficient repletion of iron stores with Ferinject[®] than with oral iron
- Faster increase in Hb with Ferinject[®] than with oral iron

Fast administration¹

• Administration of 1000 mg iron in 15 minutes

Meaningful benefits that make a difference to patients' lives

Chronic Heart Failure

• Significant improvements in exercise capacity, symptoms and quality of life were sustained over a one-year period (FAIR-HF study: Ferinject[®] vs placebo; CONFIRM-HF study: Ferinject[®] vs placebo)^{21,32}

IBD (inflammatory bowel disease)

• Significant improvement in overall guality of life from baseline (FERGIcor study: Ferinject[®] vs iron sucrose)²⁴

Non-Dialysis Chronic Kidney Disease

 Significant reduction in the requirement for additional anaemia management, such as blood transfusion or ESA therapy over a one-year period (FIND-CKD study: Ferinject® vs oral iron)²⁰

Women's Health

• Significant reduction in fatigue in non-anaemic women (PREFER study: Ferinject[®] vs placebo)¹⁰





32. Ponikowski P et al. Eur Heart J. 2014 Aug 31. pii: ehu385. [Epub ahead of print].

References: 1. Ferinject® Summary of Product Characteristics. 2. Quinibi WY. Arzneimittelforschung.

AB et al. Lancet. 1996; 348(9033): 992-6. 7. Agarwal R. Am J Nephrol. 2007; 27(6): 565-71. 8. Verdon F et al. BMJ. 2003; 326(7399): 1124. 9. Qunibi WY et al. Nephrol Dial Transplant. 2011; 26(5): 1599-607

10. Favrat B et al. PLoS One. 2014: 9(4): e94217. doi: 10.1371/iournal.pone.0094217. eCollection 2014.

11. Breymann C et al. Int J Gynaecol Obstet. 2008; 101(1): 67–73. 12. Van Wyck DB et al. Obstet Gynecol

16. Covic A and Mircescu G. Nephrol Dial Transplant. 2010; 25(8): 2722-30. 17. Bailie GR et al. Hemodial Int. 2010; 14(1): 47-54. 18. Charytan C et al. Nephrol Dial Transplant. 2013; 28(4): 953-64. 19. Onken JE

et al. Nephrol Dial Transplant. 2014; 29(4): 833–42. 20. Macdougall IC et al. Nephrol Dial Transplant. 2014

Clin Gastroenterol Hepatol. 2013; 11(3): 269-77. 26. Kulnigg-Dabsch S et al. Inflamm Bowel Dis. 2013; 19(8): 1609–16. 27. Allen RP et al. Sleep Med. 2011; 12(9): 906–13. 28. Geisser P et al. Arzneimittelforschung.

et al. Anemia. 2013; 2013: 169107. Epub 2013 Aug 29. 31. Onken JR et al. Transfusion. 2014; 54(2): 306-15.

pii: qfu201. [Epub ahead of print]. 21. Anker SD et al. NEJM. 2009; 361(25): 2436–48. 22. Geisser P and Rumyantsev V. Arzneimittelforschung. 2010; 60(6a): 373-85. 23. Kulnigg S et al. Am J Gastroenterol. 2008 103(5): 1182-92. 24. Evstatiev R et al. Gastroenterology. 2011; 141(3): 846-53.e1-2. 25. Evstatiev R et al.

2010; 60(6a): 362-72. 29. Barish CF et al. Anemia. 2012; 2012: 172104. Epub 2012 Sep 10. 30. Hussain I

2007; 110(2 Pt 1): 267-78. 13. Van Wyck DB et al. Transfusion. 2009; 49(12): 2719-28. 14. Seid MH et al. Am J Obstet Gynecol. 2008; 199(4): 435.e1-7. 15. Beshara S et al. Br J Haematol. 2003; 120(5): 853-9.

2010; 60(6a): 399-412. 3. Evstatiev R and Gasche C. Gut. 2012; 61(6): 933-52. 4. Patterson AJ et al. J Am Coll Nutr. 2001; 20(4): 337-42. 5. Brownlie T et al. Am J Clin Nutr. 2004; 79(3): 437-43. 6. Bruner









Their world.

How does Ferinject[®] help patients get back to what matters?

Ferinject® is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis must be based on laboratory tests.¹





Iron deficiency can change a patient's world...

Iron deficiency / iron deficiency anaemia (ID / IDA) can be caused by blood loss, chronic inflammation, malabsorption and malnutrition²

Impact of ID / IDA on a patient's life:

Affects key organ function:³

 Potentially leading to lasting complications

Causes fatigue and exhaustion:4,8

 Significant physical, emotional and social consequences

With Ferinject® Their world awaits





profile^{20,32}

further medical

intervention²⁰

Impacts overall health and wellbeing:⁴ Physiological effects go beyond fatigue Increases symptomatic

Impaired physical

 Reduced cognitive function and failure to concentrate

Cold intolerance

performance

burden:4-7

What are the tolerability considerations

with Ferinject?

Ferinject[®] has an established benefit-risk profile

• 26 interventional studies, published in peer-reviewed journals^{1,9-32}

• > 2,200,000 patient years' experience in post-marketing setting*

• Undesirable effects occur in <10% of Ferinject[®] subjects¹

• Majority of undesirable effects have frequencies <1%¹

• Anaphylactoid reactions occur in <0.1% of Ferinject[®] subjects¹

• Recent studies with a one-year follow-up confirm the established benefit-risk profile^{20,32}

How is Ferinject[®]

administered?

Effective recovery from ID / IDA, made convenient and manageable¹

Ferinject[®] cumulative dosing based on Hb-value and body weight:¹

Hb (g/dl)	Body weight 35 kg to <70 kg	Body weight ≥70 kg
<10	1500 mg iron	2000 mg iron
10<14	1000 mg iron	1500 mg iron
≥14	500 mg iron	500 mg iron

Ability to administer 1000 mg of iron in 15 minutes as a maximum daily dose¹

• 1000 mg of Ferinject[®] can be given up to once a week

